HOME > Clinical Trial

Clinical Trial

Clinical studies in progress

As of April 2016

Study on carcinoma of the corpus uteri

Study name: JGOG2046
Subject  Patients with stage IVb endometrial cancer
Treatment  feasibility study of induction chemotherapy using paclitaxel and carboplatin followed by reduction surgery
Accrual Period  July 2014 - December 2015
Target number of patients  50

Study on Ovarian cancer

Study name: JGOG3018
Subject  Patients with recurrent/recrudescent, platinum-resistant Mullerian carcinoma (Epithelial ovarian, primary fallopian tube, and peritoneal cancers) 
Treatment  Phase III, randomized, comparative study of liposomal doxorubicin (PLD) at 40 and 50 mg/m2 
Accrual Period  February 2010 – August 2017 
Target number of patients  Number per group: 206  Total number: 412 
Study name: GOTIC-001/JGOG3019
Subject  Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Treatment  Randomized,comparative study of weekly IV paclitaxel + IV carboplatin every 3 weeks and IV paclitaxel + IV carboplatin every 3 weeks.
Accrual Period  May 2010 – November 2016
Target number of patients  Number per group: 120 (Phase II) /746 (Phase III)
Study name: JGOG3020
Subject  Patients with surgical stage I epithelial ovarian cancer
Treatment  Phase III, randomized, comparative study of surgery plus adjuvant chemotherapy and surgery alone.
Accrual Period  July 2012 - June 2017
Target number of patients  Number per group: 310  Total number: 620
Study name: JGOG3022
Subject  with stage III-IV epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Treatment  Prospective, single arm, cohort study of standard taxane/platinum chemotherapy in combination with bevacizumab as front-line chemotherapy with following bevacizumab monotherapy for maintenance after primary or interval debulking surgery.
Accrual Period  April 2014 - March 2016
Target number of patients  400
Study name: JGOG3023
Subject  Patients who have platinum-resistant epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, defined as progression within 6 months from completion of prior chemotherapy, including Bevacizumab .
Treatment  An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without Bevacizumab in Platinum-resistant ovarian cancer patients previously treated with Bevacizumab for front-line or Platinum-sensitive ovarian cancer
Accrual Period  June 2015 - May 2017
Target number of patients  106
  • Organization Chart
  • Board of Directors
  • Crinical Trial
  • Achievement
  • JGOG COI Policy
  • Newsletter
  • Related Links

JGOG Administration Office
4F, Komatsu Building, 6-22, Kagurazaka, Shinjuku-ku,
Tokyo, 162-0825,
Japan
E-mail : info-e@jgog.gr.jp

top